Chroma Medicine

Today, we celebrate a transformative milestone as the exceptional teams at Chroma Medicine and Nvelop Therapeutics unite to form nChroma Bio. Together, we are embarking on a shared mission to redefine the future of genetic medicines. Stay tuned for what’s next and be sure to follow us on nChroma Bio. ?#Biotech #Innovation #JoiningForces #StrongerTogether

Join the Chroma team in Boston tomorrow at the 5th Annual Genome Editing Therapeutics Summit, where Shane Wright, MS, Scientist I, Platform Technologies, will discuss platform optimization through development of our PCSK9-EE, translation into an #HBV therapeutic (CRMA-1001), and more. Get the details and register here: https://lnkd.in/eVC3XsvA #EpigeneticEditing #GenomeEditing #Biotech

?…?… Three years ago, Chroma officially launched, embarking on an exciting journey to shape the future of #GeneRegulation and what a thrilling ride it has been. ?? We’ve explored uncharted areas of science and #EpigeneticEditing, fueled by the passion of our incredible team, the trust of our supportive investors, and the relentless pursuit of innovation. ? As we celebrate this milestone, we’re reminded that great things come in threes: 3 years of breakthroughs, 3 pillars of support—science, team, and investors—and 3 cheers for the future ahead! Thank you #TeamChroma and everyone who has supported us along the way.

In case you missed us in Chicago this weekend: Preclinical data presented by Yesseinia Angleró-Rodríguez, PhD at the Hepatitis B Foundation's 2024 International HBV Meeting show that a single dose of investigational drug CRMA-1001 induced durable, dose-dependent suppression of hepatitis B surface antigen expression in vivo. These results build upon the data supporting our epigenetic editing platform and position CRMA-1001 as a novel epigenetic editing drug capable of driving transformative rates of functional cure in people living with chronic hepatitis B. Read more: https://lnkd.in/euhfea2k #HBV2024 #HBV #EpigeneticEditing #GeneTherapy #Biotech

Chroma is heading to the Windy City for the Hepatitis B Foundation's 2024 International HBV Meeting. Join us to hear Yesseinia Angleró-Rodríguez, PhD, Associate Director, present new preclinical data supporting CRMA-1001, our investigational epigenetic editing drug for the treatment of chronic hepatitis B. Learn more about the meeting: https://lnkd.in/dmPjAkuY #HBV2024 #EpigeneticEditing #Hepatitis

Hello from London! Yesterday at the European Society of Cardiology Congress 2024, Chroma’s VP of Preclinical Programs, Frederic Tremblay, PhD, presented new preclinical data showcasing the best-in-class potency of our PCSK9-targeted epigenetic editor that achieved efficient and durable #PCSK9 silencing. These data underscore the strength of our epigenetic editing platform and its potential to deliver novel single-course epigenetic editing therapeutics. Learn more about data here:?https://bit.ly/3XsBX0v #ESCCongress2024 #EpigeneticEditing? #Biotech

We are so proud of our Chroma softball team! Official Cambridge 3 Division champions of the Mass Biotech Softball League. Next stop... state tournament! ????

Frederic Tremblay, PhD, Vice President, Preclinical Programs, will be heading to London to present new data highlighting the potency of our epigenetic editors targeting #PCSK9 at the @European Society of Cardiology 2024 Congress in early September. Learn more here: https://lnkd.in/eQdP5hCq #ESCCongress2024 #EpigeneticEditing? #Cardiology #Biotech

Thank you Labiotech.eu and Roohi M. for including Chroma as a leading company advancing #EpigeneticEditing and highlighting our partnership with the Whitehead Institute and exclusive licensing of their novel CHARM technology. We look forward to advancing our science to reveal what's possible with genome regulation. Read more here: https://lnkd.in/enqj5ifA #Biotech

We are committed to raising awareness for The World Hepatitis Alliance and #WorldHepatitisDay. Hepatitis is a major public health challenge impacting over 300 million people worldwide. #HBV is a virus characterized by inflammation of the liver that can cause severe liver disease and cancer. At Chroma, we are advancing our #EpigeneticEditing technology to deliver novel therapies to drive functional cure of HBV. Find ways to get involved here: https://lnkd.in/gPJ2Rq9w #ItsTimeForAction #Biotech